This study was performed to investigate whether measurement of cyclic GMP (cGMP), a marker for nitric oxide production, before and after allogeneic bone marrow transplantation (BMT) with total body irradiation (TBI) conditioning was of prognostic value. cGMP levels were monitored in 23 consecutive patients who received TBI as conditioning for BMT, and were compared with the outcome. cGMP became positive during the aplastic phase after BMT in 12 patients. In nine of these 12 patients, cGMP level decreased during the recovery phase. Eight of the nine patients survived, one dying after relapse. In three other patients, the cGMP level continued to increase even during the recovery phase and they died of severe complications. cGMP became positive on day 0 of BMT and during the leukocyte recovery phase after BMT in two and seven of the 23 patients, respectively. Subsequently, all patients died of severe complications. The two patients who were negative for cGMP both before and after BMT survived without complications. These results suggest that monitoring cGMP from early after BMT may be useful for predicting outcome and that it may be a useful prognostic marker. Bone Marrow Transplantation (2003) 31, 905-908. 
Cyclic GMP (cGMP) is a product of nitric oxide (NO). We measured cGMP in a previous study to assess severity of vascular endothelial injury caused by total body irradiation (TBI) 1 and our results showed that cGMP might be a useful marker of endothelial injury. We also reported that the outcome was poor in patients with a high cGMP level unless it decreased promptly. Since cGMP did not increase in patients not receiving TBI, irradiation seemed to be responsible for the change. It has been reported that TBI may induce upregulation of NO production by leukocytes and macrophages. 1 The present study was performed to determine when cGMP level was an indicator of outcome of bone marrow transplantation (BMT) or whether it could be used to predict the severity of complications after BMT.
Materials & methods

Patients
The subjects were 23 consecutive patients who underwent allogeneic BMT with TBI conditioning at our institution from June 1997 to August 2000. Table 1 shows the age, gender, underlying disease, disease stage, and donor type, as well as the conditioning regimens and graft-versus-host disease (GVHD) prophylaxis.
Conditioning regimen
The basic conditioning regimen was busulfan and cyclophosphamide with TBI. Busulfan was given at a dose of 4 mg/kg for 2 days, cyclophosphamide was given at 30 mg/ kg for 2 days, and TBI was given in four fractions of 3 Gy each.
GVHD prophylaxis
The basic treatment was cyclosporine plus methotrexate, and methylprednisolone 2 or cyclosporine plus methotrexate. Cyclosporine was infused from day À1 for 24 h, and was kept at a target blood level of 400-600 ng/ml until marrow engraftment, after which the dose was varied depending on the signs of GVHD. If GVHD became worse, the doses of cyclosporine and methylprednisolone were increased or cyclosporine was replaced with FK506.
Blood sampling and assays
Blood samples were collected into tubes containing 3.8% citric acid at a ratio of 1:9. After separation of plasma by centrifugation at 1500 rpm for 10 min at 41C, samples were stored at À801C. cGMP was measured by a commercially available sandwich enzyme immunoassay (R&D Systems, Inc. Minneapolis, MN, USA) (normal %0.08 pmol/ml) as an alternative to the direct measurement of NO. cGMP level was determined at the following times: (1) before conditioning; (2) On day 0 of transplantation (before infusion of bone marrow cells); (3) once during the aplastic phase after BMT (days 5-10); (4) once during the rapid white blood cell (WBC) recovery phase after BMT (days 11-20); and (5) once at the time of WBC stabilization after discontinuation of granulocyte colony-stimulating factor support (days 21-28). Values were measured in duplicate at each time and the mean was determined.
Statistical analysis
Statistical analysis was done using the Mann-Whitney U-test, and Po0.05 was considered to indicate a significant difference.
Results
Before TBI, cGMP was not detectable in any of the 23 patients. On day 0 of BMT (immediately after TBI), it became positive in only two patients. During the period of severe myelosuppression (the so-called aplastic phase from days 5 to 10 after BMT), cGMP became positive in 12 of the 23 patients. During the subsequent recovery phase (when the leukocyte count was increasing), cGMP became positive in seven patients. In two patients, cGMP remained negative throughout the course after BMT.
The outcome of BMT was studied in relation to cGMP status. In the two patients who were positive for cGMP on day 0 of BMT, their course was complicated by grade 3 acute GVHD involving the skin and intestine, respectively. One patient died of idiopathic interstitial pneumonia (IP) and the other died of complex pneumonia caused by cytomegalovirus (CMV) plus other pathogens. The former patient had grade 3 skin GVHD. The skin disease was responsive to the increased doses of the immunosuppressants with the pulse doses of methylprednisolone, but the post-BMT course was complicated with IP. This pneumonia was considered idiopathic because neither Pneumocystis carinii nor any causative viral, fungal, or bacterial agent was detected. This patient died eventually because of respiratory failure. The second patient also had grade 3 intestinal GVHD, and received the immunosuppressants in increased doses and methylprednisolone in pulse doses. The intestinal GVHD was refractory despite the treatment. In the meantime, the post-BMT course was complicated with viral, bacterial, and fungal pneumonia. This patient died eventually because of respiratory failure.
Among the 12 patients who became positive for cGMP during the aplastic phase after BMT, six developed acute GVHD (grade 2 in five patients and grade 1 in one patient), two developed IP because of CMV (CMV-IP), one relapsed, one developed thrombotic microangiopathy (TMA), and three had no complications. In all, eight patients survived and four died. Among the seven patients in whom cGMP became positive during the leukocyte recovery phase after BMT, grade 4 acute GVHD developed in two, grade 3 acute GVHD developed in one, grade 2 acute GVHD coupled with TMA occurred in one, complex pneumonia including CMV-IP occurred in one, CMV-IP occurred in one, and one patient relapsed. All seven patients died. The patients in whom cGMP remained negative throughout the course before and after BMT survived without any complications. These findings suggest that if cGMP remains negative after BMT, the prognosis is good. However, if the cGMP level begins to increase on day 0 of BMT (immediately after TBI) or during the leukocyte recovery phase, the prognosis is very poor.
For the 12 patients in whom cGMP became positive during the aplastic phase, the cGMP profile of each patient was analyzed in detail. This analysis showed that cGMP levels were lower during the recovery phase than during the cGMP after BMT H Takatsuka et al aplastic phase in the eight patients who survived. In three of the four patients who died (except for the one who died of relapse), cGMP levels were higher during the recovery phase than during the aplastic phase. In both of the patients in whom cGMP became positive on day 0 of BMT, the level increased further during the aplastic and recovery phases ( Table 2 ).
Discussion
The findings of the present study can be summarized as follows: (1) The course is often complicated when cGMP levels increase after BMT, but complications are uncommon when the cGMP levels do not increase. (2) Even if the cGMP level increases after BMT, the outcome will probably be good if the level decreases again before the recovery phase. When the cGMP level continues to increase until recovery, the prognosis is poor. (3) There is no correlation between cGMP level and severity of complications. NO is synthesized and released by vascular endothelial cells as l-arginine, which is converted into l-citrulline in association with activation of endothelial nitric oxide synthase secondary to an increase of Ca 2+ influx. It is thought that NO accelerates the formation of cGMP from GTP by activation of guanylic acid cyclase in vascular smooth muscle, after which cGMP acts as second messenger for various paracrine or autocrine effects that lead to muscular relaxation. [3] [4] [5] [6] In other words, the cGMP level seems to correlate with the amount of NO produced by the vascular endothelium. Since NO production is also correlated with the extent of stimulation of the vascular endothelium, it seems reasonable to consider that cGMP level can be measured as an index of vascular endothelial stimulation.
Accordingly, cGMP level may reflect the amount of NO produced and hence indicate vascular endothelial cell injury, with high cGMP level being a manifestation of severe treatment complications. However, a high level may also be a consequence of the upregulation of NO synthesis in leukocytes and macrophages by radiation therapy.
In either case, it seems that cGMP level can at least be considered to reflect NO level. Consequently, we compared possible organ damage secondary to an increase in NO (represented by measurement of cGMP) with various complications after BMT. Excessive nonphysiological NO production is known to reduce cardiac function by suppression of mitochondrial respiration. 7 Increased NO synthesis has also been demonstrated in conjunction with the multiplication of various viruses, 8 so viral infection might stimulate the production of NO. In the alimentary tract, it has been demonstrated that NO acts as a mediator of secretory diarrhea. 9 In the lungs, NO physiologically dilates smooth muscle in the airways and blood vessels and also regulates ciliary movement. If NO is overproduced under non-physiological conditions, it can cause airway epithelial injury, migration and invasion of eosinophils, and oedema of the bronchial mucosa secondary to increased vascular permeability. In GVHD, iNOS has been reported to inhibit the action of immunosuppressants such as CsA and FK506. 10 Thus, many of the severe or fatal complications after BMT are related to visceral disorders that can be caused by increased production of NO. Various cytokines may act as a stimulus to NO production, in agreement with our hypothesis that systemic inflammatory response syndrome plays an etiological role in the development of complications after BMT. 11 cGMP level can be used to predict outcome and complications after BMT on the following basis. An early increase in cGMP after BMT indicates stronger stimulation of NO production. If the cGMP level does not decrease, or increases during the recovery phase when the levels of inflammatory cytokines and other stimuli should be minimal, it seems likely that the stimulus is strong and persistent. A strong stimulus acting on the expanding leukocyte population may induce the production and secretion of inflammatory cytokines by macrophages, thus promoting the migration of neutrophils and their invasion, with aggravation of damage to various organs.
When cGMP remains negative throughout the course, or increases but then falls again as the leukocyte count increases, the reverse mechanism will operate and the prognosis will be good. Also, any complications will be mild.
Based on our findings and the above considerations, the outcome of BMT can be expected to be good if the cGMP level remains negative until leukopenia resolves. When cGMP increases transiently during the aplastic phase, but begins to decrease before the leukocyte count has recovered, the result is still likely to be good. However, the prognosis is poor if the cGMP level begins to increase Table 2 Outcome very early after BMT. The prognosis is also poor if the cGMP level increases while the white blood cell count is recovering, so cGMP needs to be normal during the recovery phase. Since this study was retrospective, preventive measures were not taken even if the level of cGMP changed. It is necessary, however, to treat patients undergoing BMT depending on the status of cGMP. Although GVHD is a common complication, IP, TMA, sepsis, and other problems are included among causes of death after BMT. If doses of immunosuppressants are increased simply to control GVHD, since drugs given in increased doses may worsen the post-BMT course. Consequently, the effectiveness of post-BMT immunosuppressants should be studied further to establish the timing of their administration as well as the drugs and doses to be used. The association between post-BMT cGMP status and outcome of BMT has been studied in only a few patients to date, however. Moreover, cGMP levels remained negative without any complications during the 5-year follow-up study in only two of the patients studied. Consequently, in order to predict outcomes of BMT depending on the cGMP status, it is necessary to study the association in more patients undergoing BMT.
